Pharma BD Deal Intelligence

Vasque Bio / Laekna Limited

2026 · Licensing/Option · $527M · Complete

Laekna granted Vasque Bio, a US clinical-stage biotech, an exclusive license to develop, manufacture and commercialize LAE118, an internally discovered PI3K-alpha pan-mutant selective inhibitor, in all territories outside Greater China. Laekna receives USD 10 million upfront and is eligible for up to USD 517 million in development and sales milestones plus tiered royalties, for total potential consideration of up to USD 527 million. Laekna additionally holds the right to take up to a high-teen percentage equity stake in Vasque Bio at no extra cost. LAE118 has IND clearance from both the US FDA and China's NMPA and is being advanced into clinical studies in PIK3CA-mutant solid tumors.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals